Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cytek Biosciences, Inc. Director's Dealing 2021

Jul 23, 2021

32966_dirs_2021-07-22_90201008-ccf5-4953-9270-b56ba0c071f4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Cytek BioSciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2021-07-22

Reporting Person: Yan Ming (Director, Chief Technology Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 8139792 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $0.25 2027-06-28 Common Stock (62456) Direct
Stock Option (Right to Buy) $0.92 2030-07-24 Common Stock (26666) Direct

Footnotes

F1: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 24, 2021; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.